SETD2 and cancer: SETD2 is also frequently mutated or under-expressed in several other cancer types including 15.9% of Phyllodes breast tumours, 15% of paediatric high grade gliomas, and 8–10% of pancreatic ductal adenocarcinomas [26–28].